RECURRENT SOFT TISSUE SARCOMA
Clinical trials for RECURRENT SOFT TISSUE SARCOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT SOFT TISSUE SARCOMA trials appear
Sign up with your email to follow new studies for RECURRENT SOFT TISSUE SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1 to 21) whose cancers had come back or did not respond to standard treatment. The drug works by blocking certain proteins that help cancer cells grow. The goal was to see if the drug could shrink t…
Matched conditions: RECURRENT SOFT TISSUE SARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: RECURRENT SOFT TISSUE SARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New hope for kids with tough cancers: targeted drug shows promise in early trial
Disease control CompletedThis study tested a drug called samotolisib in 18 children and teens whose cancers (solid tumors, lymphoma, or related disorders) had spread, returned, or stopped responding to treatment. Only those with specific gene mutations (TSC or PI3K/MTOR) were eligible. The goal was to se…
Matched conditions: RECURRENT SOFT TISSUE SARCOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New implant fights sarcoma recurrence in early trial
Disease control CompletedThis early-stage trial tested a new membrane placed during surgery to deliver chemotherapy directly to the tumor site in 21 adults with recurrent or advanced retroperitoneal sarcoma. The goal was to find a safe dose and see if it could delay cancer return. Results are still being…
Matched conditions: RECURRENT SOFT TISSUE SARCOMA
Phase: PHASE1 • Sponsor: CEBIOTEX • Aim: Disease control
Last updated May 15, 2026 11:57 UTC